Dr. Melanie Straubmeier (née Then)
Experience:
- Since 2020 Freelancer Quality Assurance (Nürnberg Area)
- 2020-2023 scientific associate (FAU Erlangen-Nürnberg)
- 2017-2020 Quality Assurance Manager (employee)
- 2011-2016 Studies in pharmacy
Software/IT: MS Office, SAP (MM & QM modules), Trackwise, Python, SPSS
Languages: German, English
Publications:
Then, MI; Andrikyan, W; Maas, R; Fromm, MF. The CredibleMeds® list: Usage of QT interval prolonging drugs in Germany and discordances with prescribing information. Br J Clin Pharmacol 88, 226-236 (2022). https://doi.org/10.1111/bcp.14951 (Article)
Then, MI; Andrikyan, W; Maas, R; Fromm, MF. Prescription of QT interval prolonging drugs in Germany and discrepancies between their Summary of Product Characteristics and the international CredibleMeds® database. Naunyn-Schmiedeberg´s Arch Pharmacol 395, S20 (2022). https://doi.org/10.1007/s00210-022-02205-7 (Poster)
Andrikyan, W; Then, MI; Gaßmann, K-G; Tümena, T; Dürr, P; Fromm, MF; Maas, R. Identification of diagnosis-related contraindications based on the medication plan alone. Naunyn-Schmiedeberg´s Arch Pharmacol 395, S51 (2022). https://doi.org/10.1007/s00210-022-02205-7 (Poster)
Andrikyan, W; Then, MI; Dürr, P; Jung-Poppe, L; Schuster, AK; Weisbach, L; Farker, K; Fromm, MF; Maas, R. Clarity, clinical applicability and relevance of absolute contraindications in official “Summaries of Product Characteristics” (SmPCs). Eur J Clin Pharmacol 78, S51 (2022). https://doi.org/10.1007/s00228-022-03333-y (Poster)
Then, MI; Andrikyan, W; Fromm, MF; Maas, R. Comprehensibility of contraindications in German, UK and US Summaries of Product Characteristics/Prescribing Information-a comparative qualitative and quantitative analysis. J Clin Med 11, 4167 (2022). https://doi.org/10.3390/jcm11144167 (Article)
Andrikyan, W.; Then, MI; Gaßmann, K-G; Tümena, T; Dürr, P; Fromm, MF; Maas, R. Use of medication data alone to identify diagnoses and related contraindications: application of algorithms to close a common documentation gap. Br J Clin Pharmacol 88, 5399-5411 (2022). https://doi.org/10.1111/bcp.15469 (Article)
Then, MI; Tümena, T; Sledziewska, A; Gaßmann, K-G; Maas, R; Fromm, MF. Development in prescriptions of contraindicated and potentially harmful QT interval prolonging drugs in a large geriatric inpatient cohort from 2011 to 2021. Clin Pharmacol Ther 113, 435-445 (2023). https://doi.org/10.1002/cpt.2813 (Article)
Neumann, D; Thalheim, T; Kesselmeier, M; Andrikyan, W; Farker, K; Weisbach, L; Schuster, AK; Dafonte, KK; Böhmer, A; Then, MI; Maas, R; Fromm, MF; Scherag, A; Löffler, M. POLAR Plausibilisierungskampagne – technischer Test. SMITH Science Day 2022 (2022). https://doi.org/10.3205/22smith31 (Abstract)
Andrikyan, W; Then, MI; Dürr, P; Jung-Poppe, L; Schuster, AK; Weisbach, L; Farker, K; Fromm, MF; Maas, R. Comprehensibility and clinical relevance of absolute contraindications – the perspective of German pharmacists and physicians. Naunyn-Schmiedeberg’s Arch Pharmacol 396, S48 (2023). https://doi.org/10.1007/s00210-023-02397-6 (Poster)
Weisbach, L; Schuster, AK; Hartmann, M; Dürr, P; Then, MI; Andrikyan, W; Fromm, MF; Maas, R; Farker, K. Inconsistencies of absolute drug-drug-contraindication reports: analysis of Summaries of Product Characteristics of commonly prescribed drugs. Br J Clin Pharmacol, 89, 2552-2560 (2023). https://doi.org/10.1111/bcp.15730 (Article)
Then, MI; Deutsch, B; Tümena, T; Thürmann, PA; Fromm, MF; Gaßmann, K-G; Maas, R. Prävalenz potenziell inadäquater Medikation der PRISCUS 2.0-Liste bei stationären geriatrischen Patientinnen und Patienten. Dtsch Ärztebl Int, 120, 639-640 (2023). https://www.aerzteblatt.de/archiv/234060/Praevalenz-potenziell-inadaequater-Medikation-der-PRISCUS-2-0-Liste-bei-stationaeren-geriatrischen-Patientinnen-und-Patienten (Research Letter)